RDY

Dr.Reddys
NYSE

Real-time Quotes | Nasdaq Last Sale

41.15
+0.69
+1.71%
After Hours: 41.47 +0.32 +0.78% 18:17 04/03 EDT
OPEN
40.50
PREV CLOSE
40.46
HIGH
41.20
LOW
40.37
VOLUME
116.08K
TURNOVER
--
52 WEEK HIGH
46.19
52 WEEK LOW
33.33
MARKET CAP
6.82B
P/E (TTM)
30.15
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Underperform

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RDY stock price target is 39.21 with a high estimate of 43.00 and a low estimate of 35.42.

EPS

RDY News

More
  • Why Did Amarin's Stock Fall Off a Cliff?
  • MotleyFool.com · 2d ago
  • Ranitidine products to be removed from U.S. market - FDA
  • Seeking Alpha - Article · 2d ago
  • Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment
  • Benzinga · 3d ago
  • What to watch today: Dow set to post its worst quarter in over three decades
  • CNBC.com · 3d ago

Industry

Pharmaceuticals
-0.14%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About RDY

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.
More

Webull offers kinds of Dr.Reddy's Laboratories Ltd (ADR) stock information, including NYSE:RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions.